Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of SBK001 injection for lower respiratory tract disease with viscous sputum and difficulty expectorating
CTR20263405Phase 3Active
- Sponsor
- Chengdu Shibeikang Biopharmaceutical Technology
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SBK001 in pulmonary infection, acute bronchitis, chronic bronchitis (CB), pneumonia, chronic obstructive pulmonary disease (COPD), sponsored by Chengdu Shibeikang Biopharmaceutical Technology. Started Sep 2026; status: active.
02
Drugs
SBK001
03
Conditions
pulmonary infectionacute bronchitischronic bronchitis (CB)pneumoniachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20263405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263405.